All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
DUBLIN – Shares in Neovacs SA plummeted more than 50 percent Tuesday on news that its lead immunotherapy treatment for rheumatoid arthritis (RA), TNF-Kinoid, failed to show efficacy in a phase IIb trial in 140 patients.